PMID- 31951319
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Feb
TI  - circRNA circ-CCND1 promotes the proliferation of laryngeal squamous cell 
      carcinoma through elevating CCND1 expression via interacting with HuR and 
      miR-646.
PG  - 2423-2433
LID - 10.1111/jcmm.14925 [doi]
AB  - Cyclin D1 (CCND1) is a well-known proliferation promoter that accelerates G1/S 
      transition in cancer. However, the underlying mechanism by which CCND1 is 
      regulated is still largely unknown. In this study, we identified a novel circular 
      RNA (circRNA) derived from CCND1 (circ-CCND1, hsa_circ_0023303) as a key 
      regulator for CCND1. circ-CCND1 was found to be markedly up-regulated in 
      laryngeal squamous cell carcinoma (LSCC) and closely associated with aggressive 
      clinical features and adverse prognosis. Depletion of circ-CCND1 significantly 
      inhibited LSCC cell proliferation in vitro and retarded tumour growth in vivo. 
      Regarding the mechanism, circ-CCND1 physically bound to human antigen R (HuR) 
      protein to enhance CCND1 mRNA stability; on the other hand, circ-CCND1 could act 
      as an effective sponge for miR-646 to alleviate the repression of miR-646 on 
      CCND1 mRNA. As a result, circ-CCND1 post-transcriptionally elevated CCND1 
      expression via coordinated avoidance of CCND1 mRNA decay, thereby promoting LSCC 
      tumorigenesis. Taken together, our findings uncover the essential 
      proliferation-promoting role of circ-CCND1 through regulation of the stability of 
      CCND1 mRNA in LSCC. Targeting circ-CCND1 may be a promising treatment for LSCC 
      patients.
CI  - (c) 2019 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Zang, Yanzi
AU  - Zang Y
AD  - Department of Otolaryngology, People's Hospital of Henan Province, Zhengzhou, 
      China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Otolaryngology, People's Hospital of Henan Province, Zhengzhou, 
      China.
FAU - Wan, Baoluo
AU  - Wan B
AUID- ORCID: 0000-0002-4889-1370
AD  - Department of Otolaryngology, People's Hospital of Henan Province, Zhengzhou, 
      China.
FAU - Tai, Yong
AU  - Tai Y
AD  - Department of Otolaryngology, People's Hospital of Henan Province, Zhengzhou, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200117
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (CCND1 protein, human)
RN  - 0 (ELAV-Like Protein 1)
RN  - 0 (ELAVL1 protein, human)
RN  - 0 (MIRN646 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - 0 (RNA, Messenger)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Carcinogenesis/genetics/pathology
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*genetics
MH  - Cyclin D1/*genetics
MH  - ELAV-Like Protein 1/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Prognosis
MH  - RNA, Circular/*genetics
MH  - RNA, Messenger/genetics
MH  - Up-Regulation/genetics
PMC - PMC7028846
OTO - NOTNLM
OT  - CCND1/cyclin D1
OT  - Circular RNA
OT  - mRNA stability
OT  - prognosis
OT  - proliferation
COIS- The authors declare no conflict of interest.
EDAT- 2020/01/18 06:00
MHDA- 2021/04/28 06:00
PMCR- 2020/02/01
CRDT- 2020/01/18 06:00
PHST- 2019/05/19 00:00 [received]
PHST- 2019/09/26 00:00 [revised]
PHST- 2019/12/09 00:00 [accepted]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/01/18 06:00 [entrez]
PHST- 2020/02/01 00:00 [pmc-release]
AID - JCMM14925 [pii]
AID - 10.1111/jcmm.14925 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2020 Feb;24(4):2423-2433. doi: 10.1111/jcmm.14925. Epub 2020 Jan 
      17.